Lupin's shares fell 4 percent as investors turned wary of observations issued by the US Food and Drug Administration for its Pithampur unit.
The stock touched an intraday high of Rs 844.35 and an intraday low of Rs 811.00.
According to a report by CNBC-TV18, US FDA's observations for Pithampur unit include a few observations.
The observations include:
- Failure to review unexplained discrepancy
- Written records do not include findings and follow-up
- Employees engaged in manufacturing, packaging and processing lack training
- Appropriate controls are not exercised on computers or related systems
- Equipment used in manufacturing, processing, and packaging is not of appropriate design
- Established laboratory control mechanisms are not documented.
At 09:52 hrs Lupin was quoting at Rs 824.00, down Rs 17.95, or 2.13 percent, on the BSE.Top 5 Low Price Stocks To Own For 2021: Cytokinetics, Incorporated(CYTK)
Cytokinetics, Incorporated, incorporated on August 5, 1997, is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Company's drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil.
Tirasemtiv
The Company's lead drug candidate from its skeletal muscle contractility program, tirasemtiv, is a skeletal muscle troponin activator. The Company holds the rights to tirasemtiv and is independently developing this drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). It has conducted a Phase II clinical trials program for tirasemtiv, including a Phase IIb clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Its skeletal muscle contractility program is focused on the activation of the skeletal sarcomere, the basic unit of skeletal muscle contraction.
CK-2127107
The Company is developing CK-2127107, a skeletal muscle troponin activator. The Company has conducted approximately five Phase I clinical trials of CK-2127107 and started a Phase II clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA). CK-2127107 is also being evaluated for the use in other indications associated with muscle weakness.
Omecamtiv Mecarbil
The Company's lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is a cardiac muscle myosin activator. COSMIC-HF is a Phase II, double-blind, randomized, placebo-controlled, multicenter, clinical trial designed to assess the pharmacokinetics and tolerability of omecamtiv mecarbil dosed orally in patients with heart failure and left ventricular systolic dysfunction, as well as its effects on echocardiographic measures of cardiac function. ATOMIC-AHF (Acute Treatment with Omecamtiv Me! carbil to Increase Contractility in Acute Heart Failure) is a double-blind, placebo-controlled, Phase IIb clinical trial of intravenous omecamtiv mecarbil in patients with left ventricular systolic dysfunction hospitalized with acutely decompensated heart failure.
The Company competes with Neuraltus Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Genervon Biopharmaceuticals, LLC, Orion Pharmaceuticals, Orphazyme, Mitsubishi Tanabe Pharma Corporation, Eisai Co., Ltd., MediciNova, Inc., BrainStorm Cell Therapeutics, Neuralstem, Inc., Roche, AveXis, Inc., Pfizer Inc., Bioblast Pharma, Ltd., Ligand Pharmaceuticals, Inc., GTx, Inc., Regeneron Pharmaceuticals, Inc., Eli Lilly & Company, Acceleron Pharma, Scholar Rock, Stealth Biotherapeutics, Novartis, ARCA biopharma, Inc., Bayer, Carpicor Therapeutics, Inc., Cardiorentis Ltd., Ono Pharmaceutical Company, Juventas Therapeutics, ARMGO Pharma, Inc, Trevena, Inc., Cardioxyl Pharmaceuticals, Inc., Zensun Sci & Tech, Ltd, Tenax Therapeutics, Isis Pharmaceuticals, Inc., Trophos SA, Acorda Therapeutics, Inc and Celladon Corporation.
Advisors' Opinion:- [By Motley Fool Transcribers]
Cytokinetics Inc (NASDAQ:CYTK)Q4 2018 Earnings Conference CallFeb. 21, 2019, 4:30 p.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
- [By Ethan Ryder]
Cytokinetics (NASDAQ:CYTK) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.
Dean Foods (NYSE:DF) was upgraded by analysts at ValuEngine from a strong sell rating to a sell rating.
Top 5 Low Price Stocks To Own For 2021: Fidelity Southern Corporation(LION)
Fidelity Southern Corporation operates as the holding company for Fidelity Bank, which provides financial products and services for business and retail customers primarily in the metropolitan Atlanta and northern Florida markets. The company accepts various deposit products, including savings deposits, noninterest-bearing demand deposits, interest-bearing demand deposits, money market accounts, time deposits, and brokered deposits. It also offers various loan products, including commercial and industrial loans, commercial loans secured by real estate, small business administration loans, construction and residential real estate loans, direct and indirect automobile loans, residential mortgage and home equity loans, secured and unsecured personal loans, and residential mortgage loans. In addition, the company offers Internet banking comprising online bill pay and mobile deposit, as well as Internet cash management services; and trust and wealth management services. Further, it provides cash management, remote deposit, and international trade business services; and merchant services for businesses and credit cards. Additionally, the company operates an insurance agency that offers consumer credit related insurance products; and issues trust preferred securities. As of March 31, 2015, it had a network of 45 branches. Fidelity Southern Corporation was founded in 1973 and is headquartered in Atlanta, Georgia.
Dimensional Fund Advisors LP boosted its stake in Fidelity Southern Co. (NASDAQ:LION) by 6.7% during the 1st quarter, HoldingsChannel reports. The firm owned 1,680,359 shares of the financial services provider’s stock after buying an additional 105,499 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.06% of Fidelity Southern worth $38,766,000 at the end of the most recent reporting period. ValuEngine cut shares of Fidelity Southern (NASDAQ:LION) from a strong-buy rating to a buy rating in a research note published on Wednesday morning. Van Kampen Dynamic Credit Opportunities Fund (the Fund) is a diversified, closed-end management investment company. The Fund focuses to invest primarily in loan and debt instruments (and loan-related or debt-related instruments) (collectively, credit securities) of issuers that operate in a variety of industries and geographic regions located throughout the world. The Fund's investment adviser is Van Kampen Asset Management (the Adviser). The Fund's investment subadviser is Avenue Europe International Management, L.P. (the Subadviser). The Fund will invest at least 80% of its net assets (including borrowings for investment purposes) in any combination of credit securities, including senior secured floating rate and fixed-rate loans (Senior Loans); second lien or other subordinated or unsecured floating rate and fixed-rate loans or debt, and other debt obligations, including high-yield, high-risk obligations (such as securities that are rated below investment grade by a nationally recognized credit rating organization or unrated securities that are deemed to be of comparable quality). The Fund may also invest up to 20% of its assets in structured products, including collateralized debt and loan obligations (collectively, structured products). The Fund may also invest in swaps, including credit default, total return, index and interest rate swaps. To the extent that the Fund invests in structured products or swaps that adjust exposure to credit securities, such investments will be counted for purposes of the Fund's 80% policy. The Fund may invest in credit securities of any credit quality, and may invest without limitation in obligations below investment grade. Any of the Fund's investments may be issued by non-stressed, stressed and distressed issuers, including issuers in bankruptcy, provided that with respect to the portion of the Fund's assets to be managed by the Subadviser, the Subadviser will generally not invest in securities that at the time of investment have a total! yield above the applicable Avenue-Credit Thresholds. The Fund may invest in credit securities of any maturity or duration, and although the Fund will not be managed for maturity or duration, given the nature of the Fund's portfolio, the Fund's portfolio will likely have a low average duration (generally, four years or less). In addition, the Fund may invest up to 20% of its assets in equity securities obtained through debt restructurings or bankruptcy proceedings. The Fund may utilize credit securities derivative instruments. Virtacoin (CURRENCY:VTA) traded flat against the dollar during the 24 hour period ending at 7:00 AM Eastern on March 13th. Over the last seven days, Virtacoin has traded 49.2% lower against the dollar. One Virtacoin coin can now be bought for $0.0000 or 0.00000000 BTC on cryptocurrency exchanges. Virtacoin has a market capitalization of $2,884.00 and $0.00 worth of Virtacoin was traded on exchanges in the last 24 hours. Virtacoin (CURRENCY:VTA) traded flat against the US dollar during the twenty-four hour period ending at 16:00 PM ET on February 26th. Virtacoin has a total market capitalization of $6,049.00 and approximately $0.00 worth of Virtacoin was traded on exchanges in the last 24 hours. In the last week, Virtacoin has traded flat against the US dollar. One Virtacoin coin can currently be bought for approximately $0.0000 or 0.00000000 BTC on major exchanges. Virtacoin (CURRENCY:VTA) traded down 11.7% against the U.S. dollar during the 24 hour period ending at 19:00 PM ET on September 25th. Virtacoin has a market capitalization of $26,710.00 and approximately $45.00 worth of Virtacoin was traded on exchanges in the last 24 hours. One Virtacoin coin can now be bought for $0.0000 or 0.00000000 BTC on major exchanges. Over the last seven days, Virtacoin has traded down 13.8% against the U.S. dollar. Headlines about Invesco Dynamic Credit Opportunities Fd (NYSE:VTA) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Invesco Dynamic Credit Opportunities Fd earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned press coverage about the investment management company an impact score of 46.2340823797619 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future. GenMark Diagnostics, Inc., or GenMark, is a molecular diagnostics company focused on developing and commercializing our proprietary eSensor® detection technology. References herein to "we," "us" or "our" refer to GenMark Diagnostics, Inc. and its wholly owned subsidiaries, unless the context specifically requires otherwise. Overview Our proprietary eSensor electrochemical technology enables fast, accurate and highly sensitive detection of multiple distinct biomarkers in a single sample. We are currently focused on developing and commercializing eSensor-based instruments and diagnostic tests for performing highly multiplexed reactions to simultaneously detect numerous, clinically relevant pathogens and/or genetic markers in rapidly expanding market segments. We currently sell our XT-8 instrument and related diagnostic and research tests, which collectively we refer to as our XT-8 system, in the United States. Advisors' Opinion: Get a free copy of the Zacks research report on GenMark Diagnostics (GNMK) For more information about research offerings from Zacks Investment Research, visit Zacks.com BidaskClub upgraded shares of GenMark Diagnostics (NASDAQ:GNMK) from a hold rating to a buy rating in a report released on Thursday morning. Other analysts have also issued reports about the company. Canaccord Genuity boosted their price objective on GenMark Diagnostics from $8.00 to $9.00 and gave the stock a buy rating in a report on Friday, June 29th. ValuEngine raised GenMark Diagnostics from a strong sell rating to a sell rating in a report on Friday, August 10th. Needham & Company LLC reissued a buy rating and set a $11.00 price objective on shares of GenMark Diagnostics in a report on Tuesday, July 31st. Finally, Zacks Investment Research lowered GenMark Diagnostics from a hold rating to a sell rating in a report on Wednesday, July 18th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. GenMark Diagnostics presently has an average rating of Hold and a consensus target price of $10.50. Get a free copy of the Zacks research report on GenMark Diagnostics (GNMK) For more information about research offerings from Zacks Investment Research, visit Zacks.com Virgin Galactic Holdings, Inc., an integrated aerospace company, develops human spaceflight for private individuals and researchers in the United States. It also manufactures air and space vehicles. The company's spaceship operations include commercial human spaceflight, flying commercial research, and development payloads into space. In addition, it engages in the design and development, manufacturing, ground and flight testing, and post-flight maintenance of spaceflight vehicles. The company was founded in 2017 is headquartered in Las Cruces, New Mexico. After that, though, shares pulled back. Today, they trade around the $1.50 mark. That’s even as the recent space launches by Jeff Bezos (via Blue Origin) and Richard Branson (via Virgin Galactic (NYSE:SPCE)) have put space stocks back on investor radars.Top 5 Low Price Stocks To Own For 2021: Invesco Credit Opportunities Fund(VTA)
Top 5 Low Price Stocks To Own For 2021: GenMark Diagnostics, Inc.(GNMK)
Top 5 Low Price Stocks To Own For 2021: Virgin Galactic Holdings, Inc.(SPCE)
No comments:
Post a Comment